(Q35574960)

8 August 2017

1 reference

title

Pharmacotherapy for dyslipidaemia--current therapies and future agents (English)

1 reference

8 August 2017

Pharmacotherapy for dyslipidaemia – current therapies and future agents (English)

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

author name string

Harold Bays

1

1 reference

8 August 2017

Evan A. Stein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14596646

28 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.11.1901

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Expert Opinion on Pharmacotherapy

28 March 2024

published in

1 reference

8 August 2017

volume

4

1 reference

8 August 2017

issue

11

1 reference

8 August 2017

page(s)

1901-1938

1 reference

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Pleiotropic effects of statins and their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

No changes in serum fat-soluble vitamin and carotenoid concentrations with the intake of plant sterol/stanol esters in the context of a controlled diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

The benefits of niacin in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Pathogenesis of type 2 diabetes. Insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Fish oil and glycemic control in diabetes. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

New cholesterol guidelines, new treatment challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

SCAP ligands are potent new lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Molecular identification of nicotinic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Lp-PLA2: an emerging biomarker of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Peroxisome proliferator-activated receptors and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Role of LXRs in control of lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Nuclear receptors and lipid physiology: opening the X-files

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

HDL therapy for the acute treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Aspirin beyond platelet inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Anti-obesity drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Orlistat inhibits dietary cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Pharmacotherapy of obesity: currently marketed and upcoming agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Associations between change in C-reactive protein and serum lipids during statin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Meta-analysis of corticosteroid treatment in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Nutraceutical interventions may delay aging and the age-related diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Biochemical pharmacology of functional foods and prevention of chronic diseases of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Lipid-altering drugs in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.1901

Major risk factors for cardiovascular disease: debunking the "only 50%" myth

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

Ezetimibe

4

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: the STRIP project. Special Turku Coronary Risk Factors Intervention Project

28 March 2024

23

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

Hyperlipidemia

25

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women

28 March 2024

29

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

28 March 2024

36

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

28 March 2024

37

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

28 March 2024

38

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus.

28 March 2024

43

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency

28 March 2024

47

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)

28 March 2024

52

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Lowering of HDL 2b by Probucol Partly Explains the Failure of the Drug to Affect Femoral Atherosclerosis in Subjects With Hypercholesterolemia

28 March 2024

53

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Drug interactions of lipid-altering drugs

28 March 2024

62

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women

28 March 2024

63

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits

28 March 2024

67

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Effects of high-density lipoprotein(2) on cholesterol transport and acyl-coenzyme A:cholesterol acyltransferase activity in P388D1 macrophages

28 March 2024

71

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

Lipid-lowering drugs

72

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol

28 March 2024

78

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia

28 March 2024

79

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance

28 March 2024

80

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

The effects of pantethine on fatty liver and fat distribution

28 March 2024

81

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

American Heart Journal

87

144

S33–S42

GOTTO AM

2002

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

Cholesterol absorption.

104

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers

28 March 2024

105

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.

28 March 2024

111

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis

28 March 2024

115

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

CETP and atherosclerosis

117

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters

28 March 2024

119

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

28 March 2024

122

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

C-reactive protein screening for cardiovascular disease

28 March 2024

142

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis

28 March 2024

145

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

28 March 2024

146

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

28 March 2024

151

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia

28 March 2024

154

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.1901

28 March 2024

Identifiers

1 reference

8 August 2017

1 reference